ABOUT US

The Low Institute for Therapeutics

The Low Institute for Therapeutics (LIFT) is a non-profit drug discovery institute dedicated to reducing human suffering and mortality through research and drug discovery. The institute was founded to advance and accelerate the pioneering drug discovery work conducted at Purdue University in the lab of Dr Phil Low, Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry and Biochemistry by bridging the gap between academic discovery and for-profit clinical development.

With over 50 years of research and drug discovery experience, the Low Lab at Purdue has discovered three FDA approved drugs (PLUVICTO, LOCAMETZ, CYTALUX) and five investigational drugs currently in human clinical trials, and holds over 100 approved patents.

LIFT will continue that work by advancing the next generation of discoveries from the bench to clinical trials and with the collaboration of for-profit partnerships ultimately to FDA approval and to patients.

LIFT will continue that work by advancing the next generation of discoveries from the bench to clinical trials and with the collaboration of for-profit partnerships ultimately to FDA approval and to patients.

Our best scientific discoveries have

not yet been developed

Dr. Phil Low, Purdue University

LIFT will continue that work by advancing the next generation of discoveries from the bench to clinical trials and with the collaboration of for-profit partnerships ultimately to FDA approval and to patients.

Our best scientific discoveries have not yet been developed

Dr. Phil Low, Purdue University

LIFT is focusing on disease areas that matter most, including hard-to-treat cancers, chronic kidney disease, pulmonary fibrosis, heart failure, rheumatoid arthritis, organ transplant rejection, fatty liver disease, Alzheimer’s disease, sickle cell disease and bone fractures.By building on a unique foundation of thoughtful discovery and world-class translational science, LIFT aspires to accelerate the introduction of novel drugs to address the most pressing and burdensome human diseases as one of the world’s leading drug research institutes.